GlassScriptPhysician profile
Sameera A Sbaih
NPI 1639243538
$5,734.55
in general payments reported to CMS, 2019-2025
38 companies · $1,119 in 2025
The $1,119 reported for 2025 was more than what 88% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,148 · 2020: $339 · 2021: $282 · 2022: $1,103 · 2023: $786 · 2024: $958 · 2025: $1,119.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,862.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,862.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,311.45 | 2019-2025 | Airsupra, Farxiga, Bevespi Aerosphere |
| Abbvie INC. | $848.69 | 2021-2025 | Vraylar, Ubrelvy |
| Novo Nordisk INC | $377.29 | 2019-2025 | Ozempic, Rybelsus |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $338.18 | 2022-2025 | Caplyta |
| Glaxosmithkline, LLC. | $249.63 | 2019-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Novartis Pharmaceuticals Corporation | $243.39 | 2019-2023 | |
| Amgen INC. | $238.15 | 2019-2025 | Repatha, Otezla, Otezla |
| Pfizer INC. | $224.36 | 2020-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $193.23 | 2019-2024 | Jardiance |
| Astellas Pharma US INC | $157.84 | 2023-2025 | Veozah, Myrbetriq |
| Allergan, INC. | $127.58 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $126.05 | 2019-2022 | |
| Lilly USA, LLC | $109.75 | 2022-2025 | Mounjaro, Jardiance, Zepbound |
| Dexcom, INC. | $101.89 | 2021-2025 | Dexcom G6 Transmitter |
| Sanofi-Aventis U.S. LLC | $97.83 | 2019-2023 |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lucid Diagnostics INC. | $94.92 | 2022 | |
| Exact Sciences Corporation | $89.60 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Merck Sharp & Dohme LLC | $78.65 | 2019-2023 | Janumet, Steglatro, Belsomra |
| Intra-Sana Laboratories | $72.64 | 2024 | Reltone 200 Mg, Glycate, Reltone 400 Mg |
| Abbott Laboratories | $67.07 | 2022-2023 | Freestyle Libre 2 |
| Bayer Healthcare Pharmaceuticals INC. | $65.20 | 2023-2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $56.28 | 2022 | |
| Amarin Pharma, INC. | $56.05 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $48.00 | 2019 | |
| Phathom Pharmaceuticals, INC. | $45.21 | 2024-2025 | Voquezna |
| Phadia US INC. | $37.51 | 2024-2025 | Immunocap |
| Shield Therapeutics INC | $36.63 | 2025 | |
| Kowa Pharmaceuticals America, INC. | $32.32 | 2019 | |
| Hologic Sales and Service, LLC | $31.64 | 2020-2021 | |
| Radius Health, INC. | $24.69 | 2023 | Tymlos |
| Ibsa Pharma INC. | $24.38 | 2023 | Tirosint, Licart |
| E.R. Squibb & Sons, L.L.C. | $21.51 | 2019 | |
| Sumitomo Pharma America, INC. | $21.41 | 2025 | Gemtesa |
| Daiichi Sankyo INC. | $20.97 | 2025 | Injectafer |
| Boston Scientific Corporation | $19.19 | 2025 | General - Pain Management |
| Upsher-Smith Laboratories LLC | $18.01 | 2019 | |
| Bardy Diagnostics, INC. | $15.95 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $11.41 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sameera Sbaih listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.